Hepatitis in an infant treated with octreotide for congenital hyperinsulinism

Ilana Koren*, Arieh Riskin, Winfried Barthlen, David Gillis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Congenital hyperinsulinism is characterized by hypoglycemia caused by several genetic disorders of inappropriate insulin secretion. Octreotide, an analogue of somatostatin, plays a major role in the pharmaceutical treatment of this condition. A 9-month-old infant treated with octreotide developed anicteric hepatitis with no other proven cause. After the discontinuation of this drug, the liver enzymes declined rapidly. Liver function tests should be followed in patients receiving octreotide.

Original languageEnglish
Pages (from-to)183-185
Number of pages3
JournalJournal of Pediatric Endocrinology and Metabolism
Issue number1-2
StatePublished - Feb 2013
Externally publishedYes


  • Congenital hyperinsulinism


Dive into the research topics of 'Hepatitis in an infant treated with octreotide for congenital hyperinsulinism'. Together they form a unique fingerprint.

Cite this